OKYO Pharma Limited Notice of AGM (1845L)
09 September 2021 - 04:00PM
UK Regulatory
TIDMOKYO
RNS Number : 1845L
OKYO Pharma Limited
09 September 2021
OKYO Pharma Limited
("OKYO" or the "Company")
Notice of Annual General Meeting
OKYO Pharma Limited (LSE: OKYO), the life sciences and
biotechnology company focused on the discovery and development of
novel molecules to treat inflammatory dry eye diseases and chronic
pain, is pleased to announce that it will hold its annual general
meeting ("AGM") on Monday 27 September 2021 at 10:00 a.m.
The Notice of AGM, together with a proxy form will be posted to
shareholders today. The Notice of AGM will shortly also be
available on the Company's website: www.okyopharma.com . As
previously advised, the annual report and accounts for the Company
can also be found at www.okyopharma.com .
Please note that arrangements for the AGM this year are for a
virtual meeting using an electronic platform. All voting at the
resolutions at the AGM will be conducted on a poll (a requirement
of our articles of association) which means that you should submit
your proxy (by post or, preferably, online voting) as soon as
possible. We ask that, where possible, questions which shareholders
wish to raise be submitted to info@okyopharma.com in advance.
The platform that we will be using will allow all shareholders
to attend, ask questions on the day and have the option to submit a
separate poll card at the electronic meeting but, to ease
administration, we request that proxies be lodged in advance
wherever possible.
Full details of the operation and arrangements for the AGM are
set out in the Notice of AGM.
About OKYO Pharma Limited
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is a life sciences
and biotechnology company admitted to listing on the standard
segment of the Official List of the UK Financial Conduct Authority
and to trading on the main market for listed securities of London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and chronic pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7495 2379
For further information, please visit the Company's website at
www.okyopharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOADKFBDOBKDACK
(END) Dow Jones Newswires
September 09, 2021 02:00 ET (06:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2023 to Mar 2024